开泄宣痹法治疗胸闷变异性哮喘（痰阻气痹证）的临床研究

发布时间：2018-01-08 01:25

本文关键词：开泄宣痹法治疗胸闷变异性哮喘（痰阻气痹证）的临床研究　出处：《南京中医药大学》2017年硕士论文　论文类型：学位论文

【摘要】：研究目的:基于胸闷变异性哮喘(Chesttightnessvariantasthma,CTVA)的文献研究,对运用开泄宣痹法治疗胸闷变异性哮喘进行临床观察,探讨开泄宣痹方药对于胸闷变异性哮喘的疗效,并总结导师的证治经验,以期阐明开泄宣痹法治疗胸闷变异性哮喘的临证规律及作用,为中医药治疗胸闷变异性哮喘提供临床实验依据。研究方法:此研究以江苏省中医院呼吸科门诊的胸闷变异性哮喘(痰阻气痹证)患者为研究对象,采用小样本对照试验,随机分组,中药治疗组和西药对照组比例为1:1,中药组20例,西药组20例。中药组予开泄宣痹方药治疗,疗程:4周;西药组予(布地奈德/福莫特罗干粉剂和孟鲁司特钠)治疗。疗程:4周。对比两组治疗前后各观察时间点的症状积分和FENO检测值以及PEF检测值,并观察治疗过程中的安全性。结果:开泄宣痹方药能够有效改善CTVA急性发作期痰阻气痹证患者的胸闷、咳嗽、气喘等不适症状。治疗组和对照组在治疗前后积分差与证候积分改善率方面比较,P均0.05,显示两组疗效相近;治疗组在治疗痰阻气痹证的CTVA急性发作期患者的临床综合疗效方面的症候积分对比,P0.05,显示无差异。在改善呼出气一氧化氮方面,治疗组和对照组均较治疗前有所改善,差异无统计学意义(P0.05)。整个实验过程中,未出现严重不良反应,说明开泄宣痹方对于胸闷变异性哮喘的治疗具有可靠的安全性。结论:开泄宣痹法治疗CTVA临床有效,在改善患者主要临床症状方面较西药具有优势,值得进一步研究推广。
[Abstract]:Objective: to study the literature of Chesttightiness variant asthma (CTVA) based on chest tightness variant asthma. The clinical observation was carried out on the treatment of variant asthma of chest tightness with the method of opening and releasing Xuan Bi, the curative effect of Kaixuanbi prescription on variant asthma of chest tightness was discussed, and the experience of syndrome and treatment of tutor was summarized. The purpose of this study was to elucidate the clinical syndromes and effects of the method of opening, releasing and promoting arthralgia in the treatment of chest tightness variant asthma. To provide the clinical experimental basis for the treatment of chest tightness variant asthma with traditional Chinese medicine. Methods: this study took the patient of chest tightness variant asthma (phlegm blocking qi arthralgia syndrome) in respiratory department of Jiangsu Provincial traditional Chinese Medicine Hospital as the research object. The proportion of Chinese medicine treatment group and western medicine control group was 1: 1, 20 cases in traditional Chinese medicine group, 20 cases in western medicine group, and 20 cases in western medicine group. The western medicine group was treated with budesonide / formoterol powder and montelukast sodium for 4 weeks. The symptom scores, FENO and PEF were compared between the two groups before and after treatment. And observe the safety in the course of treatment. Results: the prescription can effectively improve the acute attack of CTVA patients with phlegm blocking Qi arthralgia syndrome chest tightness cough. The difference between the treatment group and the control group in the integral difference and the improvement rate of syndrome score were 0.05, which showed that the curative effect was similar between the two groups. Treatment group in the treatment of phlegm blocking qi arthralgia syndrome of patients with acute attack of CTVA in the clinical symptoms of the comparison of P0.05, showing no difference in improving the exhalation of nitric oxide. Treatment group and control group were improved compared with before treatment, the difference was not statistically significant (P 0.05). During the whole experiment, there was no serious adverse reaction. Conclusion: Kaixiexuanbi prescription is effective in the treatment of CTVA, and has advantages over western medicine in improving the main clinical symptoms of patients. It is worth studying and popularizing further.
【学位授予单位】：南京中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R256.12

【相似文献】